| |
Group IT (n = 9)
|
Group SA (n = 6)
|
|---|
|
Age, median (range)
|
66 (57–75)
|
77 (63–90)
|
|
Gender
|
Male
|
Male
|
|
Histological cell type
| | |
|
Squamous cell carcinoma
|
6
|
1
|
|
Adenocarcinoma
|
3
|
4
|
|
Large cell carcinoma
|
0
|
1
|
|
Clinical stage
| | |
|
1
|
0
|
4
|
|
2
|
0
|
2
|
|
3
|
9
|
0
|
|
T1aN2
|
1
| |
|
T2bN2
|
3
| |
|
T3N1
|
3
| |
|
T3N2
|
2
| |
|
Pathological stage*
| | |
|
0
|
4
|
0
|
|
1
|
2
|
4
|
|
2
|
0
|
2
|
|
3
|
3
|
0
|
|
T1aN2
|
1
| |
|
T1bN2
|
1
| |
|
T3N1
|
1
| |
|
Pathological effect
| | |
|
Complete response
|
4
|
-
|
|
Major response
|
4
|
-
|
|
Minor response
|
1
|
-
|
|
Operative procedure
| | |
|
Lobectomy**
|
6
|
6
|
|
Pneumonectomy
|
3
|
0
|
- Abbreviations: IT Induction chemoradiotherapy followed by surgery, SA Surgery alone.
- *Pathological stage means post-therapeutic stage (yp–stage) in the IT group.
- **Lobectomy, including bilobectomy and lobectomy with bronchoplasty/angioplasty.
